Researchers at Tulane University, with a team of colleagues from eight other universities, have discovered a new nerve cell signaling mechanism that could transform our understanding of pain and lead ...
Thomas Yau and colleagues’ CheckMate 9DW trial has yielded unprecedented results, with nivolumab plus ipilimumab reaching an overall response rate of 36%, a median progression-free survival of 9·1 ...
A newly discovered neuron-released enzyme could transform pain treatment and reveal deeper secrets of how the brain learns.
Novo Nordisk is quietly coming out of the storm despite the prevailing pessimism, especially among retail investors. Click ...
Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a ...
Ability Biotherapeutics, a next-generation biotherapeutics company developing logic-gated antibodies for safer and more ...
A new study led by researchers at the Johns Hopkins Kimmel Cancer Center found that patients with advanced basal cell ...
A new study led by researchers at the Johns Hopkins Kimmel Cancer Center found that patients with advanced basal cell ...
A new study led by researchers at the Johns Hopkins Kimmel Cancer Center found that patients with advanced basal cell ...
Tong Dai, MD: Considering all the options, it looks like if the patient needs faster response, pembrolizumab plus lenvatinib ...
ICIs are safe and effective for HIV-positive NSCLC patients, with no significant differences in survival outcomes compared to HIV-negative patients. The efficacy of immune checkpoint inhibitors was ...
Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal second ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback